JP2020510619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510619A5 JP2020510619A5 JP2019529625A JP2019529625A JP2020510619A5 JP 2020510619 A5 JP2020510619 A5 JP 2020510619A5 JP 2019529625 A JP2019529625 A JP 2019529625A JP 2019529625 A JP2019529625 A JP 2019529625A JP 2020510619 A5 JP2020510619 A5 JP 2020510619A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sealed container
- aqueous pharmaceutical
- container according
- packaged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000012929 tonicity agent Substances 0.000 claims 5
- 239000000872 buffer Substances 0.000 claims 4
- 108010021062 Micafungin Proteins 0.000 claims 3
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 claims 3
- 229960002159 micafungin Drugs 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 239000008121 dextrose Substances 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 229940050410 gluconate Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 239000007951 isotonicity adjuster Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189549A JP2024012211A (ja) | 2016-12-16 | 2023-11-06 | ミカファンギン組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435695P | 2016-12-16 | 2016-12-16 | |
| US62/435,695 | 2016-12-16 | ||
| PCT/US2017/066652 WO2018112330A1 (en) | 2016-12-16 | 2017-12-15 | Micafungin compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189549A Division JP2024012211A (ja) | 2016-12-16 | 2023-11-06 | ミカファンギン組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020510619A JP2020510619A (ja) | 2020-04-09 |
| JP2020510619A5 true JP2020510619A5 (enExample) | 2021-01-28 |
Family
ID=60972375
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529625A Withdrawn JP2020510619A (ja) | 2016-12-16 | 2017-12-15 | ミカファンギン組成物 |
| JP2023189549A Pending JP2024012211A (ja) | 2016-12-16 | 2023-11-06 | ミカファンギン組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189549A Pending JP2024012211A (ja) | 2016-12-16 | 2023-11-06 | ミカファンギン組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12403173B2 (enExample) |
| EP (1) | EP3554474B1 (enExample) |
| JP (2) | JP2020510619A (enExample) |
| AU (1) | AU2017376960B2 (enExample) |
| DK (1) | DK3554474T3 (enExample) |
| ES (1) | ES2972008T3 (enExample) |
| FI (1) | FI3554474T3 (enExample) |
| HU (1) | HUE066069T2 (enExample) |
| PL (1) | PL3554474T3 (enExample) |
| PT (1) | PT3554474T (enExample) |
| WO (1) | WO2018112330A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111044636A (zh) * | 2019-12-30 | 2020-04-21 | 卓和药业集团有限公司 | 米卡芬净含量的分析方法 |
| US20220040092A1 (en) * | 2020-06-27 | 2022-02-10 | RK Pharma Solutions LLC | Ready to use injectable formulations of Micafungin Sodium |
| CN112710753A (zh) * | 2020-12-18 | 2021-04-27 | 卓和药业集团有限公司 | 米卡芬净有关物质的分析方法 |
| WO2024233925A1 (en) * | 2023-05-11 | 2024-11-14 | Hikma Pharmaceuticals Usa Inc. | Stable micafungin compositions |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849843A (en) | 1993-11-16 | 1998-12-15 | Baxter International Inc. | Polymeric compositions for medical packaging and devices |
| US5998019A (en) | 1993-11-16 | 1999-12-07 | Baxter International Inc. | Multi-layered polymer structure for medical products |
| MX9702531A (es) | 1994-10-07 | 1997-06-28 | Fujisawa Pharmaceutical Co | Compuesto nuevo. |
| TWI233805B (en) | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| EP1193261A1 (en) | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| US6991800B2 (en) * | 2002-06-13 | 2006-01-31 | Vicuron Pharmaceuticals Inc. | Antifungal parenteral products |
| CN103360486A (zh) | 2004-08-18 | 2013-10-23 | 诺瓦生命科学有限公司 | 包含含有精氨酸和/或赖氨酸的基序的抗微生物肽 |
| WO2008137128A2 (en) | 2007-05-03 | 2008-11-13 | Northeastern University | Methods of treating fungal infections |
| AU2013254940A1 (en) | 2008-04-21 | 2014-01-16 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| MX2010012451A (es) | 2008-05-15 | 2010-12-07 | Baxter Int | Formulaciones farmaceuticas estables. |
| GB0817121D0 (en) | 2008-09-18 | 2008-10-29 | Univ St Andrews | Anti-fungal therapy |
| WO2010110686A1 (en) | 2009-03-27 | 2010-09-30 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy |
| US20110071072A1 (en) * | 2009-08-28 | 2011-03-24 | Georgetown University, A Congressionally Chartered Institution Of Higher Education | Antifungal Bone Cements |
| CN102614492B (zh) * | 2011-01-31 | 2013-12-11 | 上海天伟生物制药有限公司 | 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物 |
| CN102775476B (zh) * | 2011-05-12 | 2015-01-07 | 上海天伟生物制药有限公司 | 一种米卡芬净钠盐的制备方法 |
| CN102512379B (zh) * | 2011-12-16 | 2017-03-08 | 深圳市健元医药科技有限公司 | 一种新型棘白菌素类抗真菌药物组合物及其制备方法 |
| SI3677252T1 (sl) | 2012-03-19 | 2024-02-29 | Cidara Therapeutics, Inc. | Sheme odmerjanja za spojine iz razreda ehinokandinov |
| DK3240529T3 (da) * | 2014-12-31 | 2022-02-28 | Galenicum Health S L U | Stabile farmaceutiske sammensætninger omfattende micafungin |
| CN108290845B (zh) * | 2015-10-07 | 2021-08-03 | 大日本住友制药株式会社 | 嘧啶化合物 |
| IN2015MU03858A (enExample) * | 2015-10-10 | 2015-10-23 | Gufic Biosciences Ltd |
-
2017
- 2017-12-15 AU AU2017376960A patent/AU2017376960B2/en active Active
- 2017-12-15 PL PL17829412.0T patent/PL3554474T3/pl unknown
- 2017-12-15 FI FIEP17829412.0T patent/FI3554474T3/fi active
- 2017-12-15 JP JP2019529625A patent/JP2020510619A/ja not_active Withdrawn
- 2017-12-15 PT PT178294120T patent/PT3554474T/pt unknown
- 2017-12-15 US US15/843,634 patent/US12403173B2/en active Active
- 2017-12-15 EP EP17829412.0A patent/EP3554474B1/en active Active
- 2017-12-15 WO PCT/US2017/066652 patent/WO2018112330A1/en not_active Ceased
- 2017-12-15 ES ES17829412T patent/ES2972008T3/es active Active
- 2017-12-15 DK DK17829412.0T patent/DK3554474T3/da active
- 2017-12-15 HU HUE17829412A patent/HUE066069T2/hu unknown
-
2023
- 2023-11-06 JP JP2023189549A patent/JP2024012211A/ja active Pending
-
2025
- 2025-07-18 US US19/274,054 patent/US20250345386A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510619A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| HRP20110801T1 (hr) | Tekući oblik fsh | |
| PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| JP2013511522A5 (enExample) | ||
| US8431539B2 (en) | Formulations of daptomycin | |
| EA201492021A1 (ru) | Антительный состав | |
| JP2019529457A5 (enExample) | ||
| ES2875307T3 (es) | Composición farmacéutica que contiene un compuesto derivado del ácido piridilaminoacético | |
| JP2018502910A5 (enExample) | ||
| UA109421C2 (uk) | Фармацевтична композиція, яка містить ліганди сигма-рецептора | |
| HRP20240004T1 (hr) | Formulacije agonista guanilat ciklaze c i postupci uporabe | |
| HRP20250382T1 (hr) | Farmaceutski pripravak koji sadrži karbetocin | |
| JP2014530801A5 (enExample) | ||
| JP2016503058A5 (enExample) | ||
| RU2017103632A (ru) | Суспензионные составы циклоспорина а для субконъюнктивального и периокулярного введения | |
| RU2012134065A (ru) | Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления | |
| JP2019533679A5 (enExample) | ||
| AR093297A1 (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf | |
| JP2013518051A5 (enExample) | ||
| ZA202102986B (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
| HRP20110162A8 (hr) | Spojevi koji sadrže amlodipin i bisoprolol | |
| FI3554474T3 (fi) | Mikafungiinikoostumuksia | |
| JP2018188399A (ja) | テリパラチドのプレフィルドシリンジ製剤 | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica |